Medicologic has received the CIR (credit d’impôt recherche) approval by the French Ministry of Research and Higher Education as one of very few Scandinavian med-tech consultancies.
We are really proud of this stamp of approval, says Martin Thomsen, COO of Medicologic
The tax credit amount given by the French authorities is adjusted according to the degree of basic research and novelty of the R&D, but in some instances it can be the full project costs.
Therefore, this should motivate Medicologic clients with plans in France to look into the possibilities of reducing overall R&D spending.
Martin Thomsen, COO of Medicologic explains: “We are really proud of this stamp of approval – owing to a consistent and extensively documented R&D strategy it shows the high standards of our R&D expertise. I sincerely hope even more clients will wish to engage in new exciting projects in France together with Medicologic.”
Medicologic is a consultancy focused on medical devices for the med-tech as well as pharma industry which currently is undergoing a transformation from pure drugs to different kinds of drug/device combinations – not least driven by the biosimilar evolution. Several clients are already benefitting from Medicologic’s many years of experience in the industry – providing R&D expertise as well as global support for RA and QA, which most often is closely linked to even the early development phases.
For more information:
Martin Thomsen
Chief Operating Officer, Research & Development
Direct (+45) 22 47 72 12
mt@medicologic.com